Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Manegold C et al. – Pemetrexed is a novel multi–targeted antifolate that is used in the treatment of both malignant pleural mesothelioma and non–small–cell lung cancer (NSCLC). Ongoing trials aim to establish the place of pemetrexed in maintenance, in combination with other ‘targeted agents’, in adjuvant therapy in early NSCLC and in concurrent radio/chemotherapy.

Related Articles

Lung cancer: a biologically different disease in women?
Women's Health, 10/30/09    Relevance Score: 83%

HRQoL changes, mood disorders and satisfaction after treatment in an unselected population of patients with lung cancer
The Clinical Respiratory Journal, 11/13/09    Relevance Score: 82%

Image-Guided Radiofrequency Ablation of Lung Neoplasm in 100 Consecutive Patients by a Thoracic Surgical Service
Annals of Thoracic Surgery, 10/23/09    Relevance Score: 82%

Noninvasive detection of lung cancer by analysis of exhaled breath
BMC Cancer, 10/09/09    Relevance Score: 82%

CYP2E1 Rsa I/Pst I polymorphism is associated with lung cancer risk among Asians
Lung Cancer, 10/06/09    Relevance Score: 82%

Today in Pharmacology/Therapy...keeping you current

Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09

ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
Expert Review of Anticancer Therapy, 12/04/09

Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address